About Us

Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome.  Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.  

Read more



April 15, 2015

Bruce N. Cronstein, MD, Joins Revive Therapeutics as Medical Advisor

Read more
March 05, 2015

Revive Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets Inc.

Read more
February 26, 2015

Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease

Read more
February 11, 2015

Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2014 

Read more
January 29, 2015

Revive Therapeutics Announces Initiation of a Phase 2A Study of REV-002 (Bucillamine) in Patients With Gout

Read more
Corporate presentation